Aptar Pharma has announced that the Zetonna nasal aerosol device recently launched in the US includes a customized Aptar Landmark dose indicator, the result of a six-year collaboration with Sunovion. Zetonna is delivered by a pressurized metered dose inhaler, and the FDA recommends that all new pMDI products have an integrated dose counter.
Aptar Pharma Prescription Division VP of Marketing and Communication Pierre Carlotti commented, “The collaboration between Aptar Pharma and Sunovion is a source of great satisfaction, and we are particularly proud to have developed this customized device for Zetonna.”
Read the Aptar press release.
